Status:
COMPLETED
A-protein Levels in Adult and Pediatric Brain Tumor Patients
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
Conditions:
Malignant Childhood Central Nervous System Neoplasm
Eligibility:
All Genders
Up to 77 years
Brief Summary
The purpose of this study is to evaluate the sensitivity and specificity of "A-PROTEIN" levels in patients with brain tumors. A-PROTEIN levels will be analyzed both pre and post treatment. Levels in b...
Detailed Description
* Patients will be identified at the time of presentation to their neurologist, neurosurgeon or oncologist. * Blood or cerebrospinal fluid will be collected for this study only when they are being col...
Eligibility Criteria
Inclusion
- All patients with possible malignant or benign lesions of the central nervous system will be included.
- There are no restrictions with respect to treatment protocols or prior therapy.
- Patients will be identified after presentation to the neurosurgical, neurological or oncologic services at participating centers. Any patient with evidence of a central nervous system tumor will be eligible. Individuals without evidence of CNS tumors are also eligible, in order to provide blinded controls.
- A signed informed consent will be requested and required for participation.
- There is no age, sex, or ethnic origin restrictions in this protocol. Patients who choose not to participate in the study will continue to have their regular care as defined by their treating team. Patients who speak foreign languages are eligible as long a translator can be found to ensure proper consent has been obtained.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
June 1 1998
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00165542
Start Date
June 1 1998
End Date
August 1 2009
Last Update
November 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institite
Boston, Massachusetts, United States, 02115